TearLab Corporation (TEAR)
(Delayed Data from OTC)
$0.06 USD
0.00 (0.00%)
Updated Jul 9, 2020 09:35 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
TearLab Corporation [TEAR]
Reports for Purchase
Showing records 21 - 40 ( 165 total )
Company: TearLab Corporation
Industry: Medical - Instruments
Regulatory Approval in Mexico; CE Mark for Next-Gen System Near Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
Regulatory Approval in Mexico; CE Mark for Next-Gen System Near Term; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: TearLab Corporation
Industry: Medical - Instruments
Q3 results slightly ahead, so far the sales model transition appears successful
Provider: Feltl & Company
Analyst: HAYNOR B
Company: TearLab Corporation
Industry: Medical - Instruments
3Q16 Financial Results; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: TearLab Corporation
Industry: Medical - Instruments
3Q16 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
Company: TearLab Corporation
Industry: Medical - Instruments
AAO 2016 Meeting Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
AAO 2016 Meeting Update; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: TearLab Corporation
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
Company: TearLab Corporation
Industry: Medical - Instruments
Co-Promotion With Clinically Proven Nutriceutical for Dry Eye; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
Co-Promotion With Clinically Proven Nutriceutical for Dry Eye; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: TearLab Corporation
Industry: Medical - Instruments
Q2 results light, but future looks bright after transitional quarter
Provider: Feltl & Company
Analyst: HAYNOR B
Company: TearLab Corporation
Industry: Medical - Instruments
Device Footprint and Revenue Per Device Increase Amidst Sales Model Change; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: TearLab Corporation
Industry: Medical - Instruments
Device Footprint and Revenue Per Device Increase Amidst Sales Model Change; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
2016 Outlook Lowered on Sales Transition Challenges; Moving to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: TearLab Corporation
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TearLab Corporation
Industry: Medical - Instruments
New Shire drug approval catalyst for TearLab, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: TearLab Corporation
Industry: Medical - Instruments
We are Initiating Coverage at Buy with $2 Price Target
Provider: Rodman & Renshaw, Co.